Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 5

If you are unable to see the message below, click here to view.

Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions: http://bit.ly/1xXPzzM
TABLE OF CONTENTS
May 2015 Volume 12 Number 5
Impact Factor 15.696 *	In this issue Editorial Research Highlights News and Views Reviews Correspondence Perspectives Also this month  Featured article: Using tumour phylogenetics to identify the roots of metastasis in humans Kamila Naxerova & Rakesh K. Jain
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Breast Cancer Screening Conference Learning from the past, planning for the future June 18-20, 2015 Dublin, Ireland This conference will focus on using current knowledge in breast screening and its outcomes to inform future screening practice for breast cancer and its treatment. Click here for more information:
EDITORIAL		Top
Understanding metastasis Lisa Hutchinson p247 | doi:10.1038/nrclinonc.2015.71 Full Text | PDF
RESEARCH HIGHLIGHTS Top Genetics: Stromal signatures drive the oncogenic phenotype of colorectal cancer Published online: 17 March 2015 p249 | doi:10.1038/nrclinonc.2015.45 PDF CNS cancer: Visualizing secrets of glioma Published online: 10 March 2015 p250 | doi:10.1038/nrclinonc.2015.41 PDF Genetics: CUP: discovering genetic opportunities Published online: 17 March 2015 p251 | doi:10.1038/nrclinonc.2015.43 PDF Risk factors: HRT increases risk of ovarian cancer Published online: 03 March 2015 p251 | doi:10.1038/nrclinonc.2015.44 PDF Lung cancer: Driver-mutation-dependent stratification: learning from STAT3 Published online: 17 March 2015 p251 | doi:10.1038/nrclinonc.2015.52 PDF Haematological cancer: BCL-ABL1 resistance mutation—breakthrough with axitinib Published online: 10 March 2015 p252 | doi:10.1038/nrclinonc.2015.42 PDF Breast cancer: Shielding the ovaries from chemotherapy in breast cancer Published online: 24 March 2015 p252 | doi:10.1038/nrclinonc.2015.55 PDF IN BRIEF Genetics: Chromatin organization heavily influences mutation patterns | Lung cancer: Nivolumab is a safe and effective treatment of NSCLC | Urological cancer: Urinary methylation signature predicts prostate cancer risk | Genetics: CEP72 variants underly vincristine-induced neuropathy PDF Clinical Oncology JOBS of the week Postdoctoral Fellowship in Functional Genomics Memorial Sloan Kettering Cancer Center (MSKCC) Laboratory Investigator Division of Hematologic Neoplasia Dana-Farber Cancer Institute and the Department of Medicine at Brigham and Women's Hospital Post-doctoral fellow University of California - San Francisco Postdoctoral Fellow Emory University Tenure, Tenure-track position in Childhood Cancer Research Greehey Children's Cancer Research Institute More Science jobs from Clinical Oncology EVENT 4th International Conference on Immunotherapy in Pediatric Oncology (CIPO2015) 25.09.15 Seattle, USA More science events from
NEWS AND VIEWS		Top
Prostate cancer: MR-TRUS fusion biopsy—defining a new standard Eric A. Klein Published online: 14 April 2015 p253 | doi:10.1038/nrclinonc.2015.70 The widespread use of PSA screening and transrectal ultrasound (TRUS)-guided prostate biopsy has resulted in an epidemic of overdetection and overtreatment of prostate cancer. The use of targeted magnetic resonance (MR) and ultrasound fusion guided prostate biopsy promises to improve the detection rate of high-risk prostate cancer—reducing the issue of overdetection and overtreatment. Full Text | PDF
Risk factors: After gestational chemotherapy, the kids are all right Fedro A. Peccatori, Giacomo Corrado & Monica Fumagalli Published online: 14 April 2015 p254 | doi:10.1038/nrclinonc.2015.66 When a pregnant woman is diagnosed with cancer, clinical management is complicated by concerns about the possible detrimental effects of cancer treatments on pregnancy outcome and the health of the baby. Evidence about the outcomes of children after maternal chemotherapy for cancer during pregnancy is growing and we can say 'the kids are all right'. Full Text | PDF
Lung cancer: Implementing lung-cancer screening—oncological 'grey areas' Vivek Verma Published online: 07 April 2015 p256 | doi:10.1038/nrclinonc.2015.65 Owing to the institution of annual low-dose CT for lung cancer screening in the USA, the presumed increase in detection of early stage lung cancers elicits many questions about so-called 'grey areas' of the management of this disease that have been inadequately addressed to date. Herein, important and potentially difficult ambiguous cases that oncologists might come across are discussed. Full Text | PDF
REVIEWS		Top
Using tumour phylogenetics to identify the roots of metastasis in humans Kamila Naxerova & Rakesh K. Jain Published online: 20 January 2015 p258 | doi:10.1038/nrclinonc.2014.238 The routes and timing of metastatic dissemination during cancer progression remain shrouded in mystery. However, phylogenetic studies are beginning to shed new light on this process and various models have been proposed. In this Review, Kamila Naxerova and Rakesh Jain discuss the hypothesized trajectories of metastasis, and examine the extent to which the current phylogenetic evidence support these models. In addition, the experimental techniques of lineage tracing, their strengths and weaknesses, and future directions for studies using such methods are discussed. Abstract | Full Text | PDF
Can oncology recapitulate paleontology? Lessons from species extinctions Viola Walther, Crispin T. Hiley, Darryl Shibata, Charles Swanton, Paul E. Turner & Carlo C. Maley Published online: 17 February 2015 p273 | doi:10.1038/nrclinonc.2015.12 The evolutionary biology of cancers and organismal species are similar: in both cases, a genetically diverse population mutates and evolves through natural selection. In addition, driving both species and cancers to extinction is extremely difficult. Nevertheless, greater than 99.9% of species that have lived on Earth are now extinct, and the parallels between tumours and organismal evolution suggest that understanding species extinction through paleontology could teach us much about how to eradicate cancers. In this Review, the selective pressures that have driven species extinct and the characteristics of species that make them resistant to extinction are described, and how these factors can be translated to cancers in order to develop improved approaches to therapy and prognosis is discussed. Abstract | Full Text | PDF
Minimal residual disease in multiple myeloma: bringing the bench to the bedside Sham Mailankody, Neha Korde, Alexander M. Lesokhin, Nikoletta Lendvai, Hani Hassoun, Maryalice Stetler-Stevenson & Ola Landgren Published online: 27 January 2015 p286 | doi:10.1038/nrclinonc.2014.239 Substantial improvements in the outcomes of patients with multiple myeloma have created a need for more sensitive diagnostic tests for minimal residual disease (MRD) in this patient population. This Review describes and compares the validity of current clinically used tests for MRD, and highlights the significantly improved outcomes of patients who are known to be MRD negative. Possible opportunities and challenges to the clinical use and widespread implementation of highly sensitive MRD testing are discussed. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Intermediate-stage HCC—upfront resection can be feasible Jian-Hong Zhong, Shi-Dong Lu, Yan-Yan Wang, Liang Ma & Le-Qun Li Published online: 07 April 2015 p295 | doi:10.1038/nrclinonc.2014.122-c3 Full Text | PDF
REPLY		Top
Intermediate-stage HCC—upfront resection can be feasible Alejandro Forner, Marine Gilabert, Jordi Bruix & Jean-Luc Raoul Published online: 07 April 2015 p295 | doi:10.1038/nrclinonc.2014.122-c4 Full Text | PDF
PERSPECTIVES		Top
OPINION Ki67—no evidence for its use in node-positive breast cancer Fabrice Andre, Monica Arnedos, Aicha Goubar, Amal Ghouadni & Suzette Delaloge Published online: 17 March 2015 p296 | doi:10.1038/nrclinonc.2015.46 Several guidelines propose the use of Ki67 expression to select which patients with early stage breast cancer and 1-3 positive nodes should not receive adjuvant chemotherapy. In this Perspective, the authors discuss why, in 2015, the oncologist should not rely on the use of this biomarker for decision-making in this patient population—owing to lack of analytical validity of Ki67 staining, its poor performance for prognostic purposes, and no strong evidence indicating that Ki67 staining predicts the efficacy of adjuvant chemotherapy. Abstract | Full Text | PDF
OPINION After counterfeit Avastin®—what have we learned and what can be done? Tim K. Mackey, Raphael Cuomo, Camille Guerra & Bryan A. Liang Published online: 03 March 2015 p302 | doi:10.1038/nrclinonc.2015.35 Since February 2012, the FDA has identified widespread infiltration of counterfeit bevacizumab into the US drug-supply chain. This Perspectives uses this case study to highlight the continued lack of information, knowledge, and solutions necessary to protect patients against future breaches in the drug-supply network, as well as the need for collaborative efforts to enhanced surveillance for counterfeit medicines and improve communication of risk information. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.